Drugs / Casdatifan
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06919991 | May → Oct 2025 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06191796 | Jan 2024 → May 2025 | clear cell renal carcinoma | Exelixis | Terminated | No outcome recorded |
| Phase 1 | NCT05999513 | Aug → Oct 2023 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05536141 | Oct 2022 → Mar 2029 expected | clear cell renal carcinoma | Arcus Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05117554 | Nov 2021 → Feb 2023 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07397611 | Mar 2026 → Jan 2028 expected | renal cell carcinoma | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07011719 | Sep 2025 → Apr 2028 expected | clear cell renal carcinoma | Arcus Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07000149 | Jul 2025 → Feb 2030 expected | clear cell renal carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Casdatifan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06919991 ↗ |
| Known as | AB521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06191796 ↗ |
| Action | Inhibit | “highly potent and selective tetralin-based HIF-2α inhibitor” PMID 42246926 ↗ Jun 2026 |
| Modality | Small molecule | “highly potent and selective tetralin-based HIF-2α inhibitor” PMID 42246926 ↗ Jun 2026 |
| Route | Oral | “casdatifan orally with water under fasting conditions” NCT05117554 ↗ |